Want to see AUPH full AI Analyst Report?
Top Page
Aurinia Pharmaceuticals
(NASDAQ:AUPH)
Select Model
Select Model
Rating:77Outperform
Price Target:
$17.50
▲(14.01% Upside)
Action:Reiterated
Date:08/20/26
The score is driven primarily by markedly improved financial performance (profitability and free-cash-flow inflection with improving balance sheet strength) and supportive valuation from a low P/E. These positives are tempered by weaker intermediate technical momentum (negative MACD and price below key moving averages). Corporate events add a meaningful tailwind via extended exclusivity from the Teva settlement and stable shareholder support.
Positive Factors
Growing LUPKYNIS Commercial Sales
Reiterated revenue and product-sales growth indicates continued LUPKYNIS adoption and provides a durable commercial base. Sustained growth should improve operating leverage and strengthen Aurinia’s ability to fund its pipeline.
Negative Factors
Uncertain Sustainability of Recent Profitability
The recent earnings improvement has a short track record, and unusually high margins may not fully represent recurring product economics. Episodic license or royalty income could make future profitability less predictable than reported results suggest.
Read all positive and negative factors
Positive Factors
Negative Factors
Growing LUPKYNIS Commercial Sales
Reiterated revenue and product-sales growth indicates continued LUPKYNIS adoption and provides a durable commercial base. Sustained growth should improve operating leverage and strengthen Aurinia’s ability to fund its pipeline.
Read all positive factors
Aurinia Pharmaceuticals Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down revenue by different business segments, highlighting which areas are driving growth and profitability. This helps assess the company's strategic focus and potential areas of risk or opportunity.
Breaks down revenue by different business segments, highlighting which areas are driving growth and profitability. This helps assess the company's strategic focus and potential areas of risk or opportunity.
Data provided by:
The Fly
The FlyAurinia Pharmaceuticals (AUPH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.04B
Dividend YieldN/A
Average Volume (3M)1.66M
Price to Earnings (P/E)6.8
Beta (1Y)0.26
Revenue Growth19.76%
EPS Growth444.46%
CountryUS
Employees128
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.37
Shares Outstanding133,051,160
10 Day Avg. Volume901,393
30 Day Avg. Volume1,656,012
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.69
Price to Sales (P/S)7.57
P/FCF Ratio15.83
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$16.00Price Target Upside4.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.95
Revenue Forecast (FY)$331.35M
Aurinia Pharmaceuticals Business Overview & Revenue Model
Company Description
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical so...
How the Company Makes Money
Aurinia primarily makes money by selling LUPKYNIS (voclosporin). Revenue is generated from product sales to customers in markets where the drug is commercialized, with net sales reflecting typical pharmaceutical adjustments such as rebates, discou...
Aurinia Pharmaceuticals Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call highlights robust commercial momentum for LUPKYNIS with double-digit top-line growth, materially improved cash generation, a strong balance sheet and share repurchases. Management provided constructive 2026 guidance and disclosed promising early clinical results for aritinercept. Offsetting these positives are a significant one-time tax benefit that materially boosted reported net income, termination of a pediatric study (creating regulatory follow-up risk), emerging competition (Gazyva), limited near-term transparency on quarterly performance, and early-stage development uncertainties (ADAs). Overall, the positives—sustained product revenue growth, strong cash flow, and advancing pipeline—outweigh the headwinds, though some risks remain.Positive Updates
Strong LUPKYNIS Commercial Growth
Net product sales of LUPKYNIS for full year 2025 were $271.3M, up 25% year-over-year from $216.2M. Management reported LUPKYNIS sales grew 25% in 2025 and expects 2026 net product sales of $305M–$315M (up 12%–16% vs. 2025).
Negative Updates
Net Income Heavily Influenced by One-Time Tax Benefit
Q4 2025 net income included an income tax benefit of $175.1M and FY2025 included $173M related to the release of a valuation allowance on deferred tax assets. Management notes this benefit primarily drove the large YoY net income and EPS improvements, indicating part of the profitability gain is non-recurring.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong LUPKYNIS Commercial Growth
Net product sales of LUPKYNIS for full year 2025 were $271.3M, up 25% year-over-year from $216.2M. Management reported LUPKYNIS sales grew 25% in 2025 and expects 2026 net product sales of $305M–$315M (up 12%–16% vs. 2025).
Read all positive updates
Company Guidance
On the call Aurinia provided 2026 guidance of total revenue of $315–$325 million (up 11%–15% vs. 2025) and net product sales of LUPKYNIS of $305–$315 million (up 12%–16% vs. 2025); that outlook is framed by FY‑2025 results of total revenue $283.1M (up 20% vs. $235.1M in 2024, or +26% excluding a $10M 2024 milestone), LUPKYNIS sales $271.3M (up 25% YoY), net income $287.2M (driven in part by a $173M income tax benefit), diluted EPS $2.07, operating cash flow $135.7M (up 206% YoY), cash and investments of $398M, and recent share repurchases of 12.2M shares for $98.2M that reduced fully diluted shares from 149.8M to 139.7M; Q4 highlights included revenue $77.1M, LUPKYNIS sales $74.2M (both +29% YoY), Q4 net income $210.8M (driven by a $175.1M tax benefit), diluted EPS $1.53, and Q4 operating cash flow $45.7M (up 52% YoY).Aurinia Pharmaceuticals Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
82
Very Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 311.51M | 283.06M | 235.13M | 175.51M | 134.03M | 45.60M |
| Gross Profit | 281.47M | 250.39M | 206.88M | 161.37M | 128.37M | 44.51M |
| EBITDA | 188.22M | 127.76M | 31.73M | -63.05M | -103.65M | -177.44M |
| Net Income | 314.11M | 287.20M | 5.75M | -78.02M | -108.18M | -180.97M |
Balance Sheet | ||||||
| Total Assets | 792.26M | 751.59M | 550.64M | 548.06M | 470.86M | 543.37M |
| Cash, Cash Equivalents and Short-Term Investments | 443.12M | 398.00M | 358.48M | 350.49M | 389.39M | 466.08M |
| Total Debt | 60.42M | 74.81M | 79.37M | 97.61M | 8.09M | 8.74M |
| Total Liabilities | 177.40M | 170.26M | 173.17M | 170.11M | 65.42M | 64.28M |
| Stockholders Equity | 614.86M | 581.33M | 377.48M | 377.95M | 405.44M | 479.09M |
Cash Flow | ||||||
| Free Cash Flow | 173.58M | 135.41M | 44.11M | -34.18M | -79.82M | -159.19M |
| Operating Cash Flow | 173.75M | 135.66M | 44.39M | -33.46M | -79.53M | -157.69M |
| Investing Cash Flow | 12.42M | -32.77M | 39.26M | -6.71M | -60.63M | -103.87M |
| Financing Cash Flow | -59.65M | -106.11M | -49.09M | -5.13M | 2.43M | 221.11M |
Aurinia Pharmaceuticals Technical Analysis
Positive
15.35
Price Trends
15.89
Positive
15.78
Positive
15.38
Positive
Market Momentum
-0.04
Negative
57.96
Neutral
40.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUPH, the sentiment is Positive. The current price of 15.35 is above the 20-day moving average (MA) of 15.31, below the 50-day MA of 15.89, and below the 200-day MA of 15.38, indicating a bullish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 57.96 is Neutral, neither overbought nor oversold. The STOCH value of 40.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AUPH.
Aurinia Pharmaceuticals Risk Analysis
Aurinia Pharmaceuticals disclosed 33 risk factors in its most recent earnings report. Aurinia Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aurinia Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $2.04B | 6.82 | 59.00% | ― | 19.76% | 444.46% | |
57 Neutral | $2.48B | -7.00 | 101.55% | ― | 68.72% | -737.08% | |
57 Neutral | $3.28B | -9.56 | -52.36% | ― | -97.27% | -44.90% | |
54 Neutral | $1.31B | -31.51 | 78.60% | ― | 30.46% | -223.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.90B | -13.70 | -9.96% | ― | -20.44% | -349.84% | |
48 Neutral | $1.85B | -204.44 | -2.35% | ― | 20.19% | ― |
* Healthcare Sector Average
AUPH
Aurinia Pharmaceuticals
16.17
4.16
34.64%
BCRX
BioCryst
10.07
1.69
20.17%
CLDX
Celldex
41.70
20.81
99.62%
MNKD
MannKind
4.40
0.42
10.71%
SRPT
Sarepta Therapeutics
19.73
-0.85
-4.13%
IMCR
Immunocore Holdings
36.86
4.37
13.45%
Aurinia Pharmaceuticals Corporate Events
Business Operations and StrategyLegal Proceedings
Aurinia, Teva Reach Voclosporin Patent Litigation Settlement
Positive
Aug 19, 2026
On August 19, 2026, Aurinia Pharmaceuticals Inc. announced it had entered into a settlement agreement with Teva Pharmaceuticals to resolve U.S. patent infringement litigation tied to Teva’s Abbreviated New Drug Application for generic 7.9 mg...
Executive/Board ChangesShareholder Meetings
Aurinia Shareholders Back Board Slate and Governance Measures
Positive
Jun 4, 2026
At its virtual annual general meeting on June 3, 2026, Aurinia Pharmaceuticals shareholders elected Kevin Tang, Jeffrey Bailey, Kathy Goetz, Craig Johnson and Tina S. Nova to the board of directors for terms lasting until the 2027 meeting, with ea...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.